Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
Returns on capital
Cue Biopharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-100.6%
avg -88.4%
ROIC
-86.6%
avg -71.5%
ROA
-63.0%
avg -61.2%
Analysis
ROA is currently the strongest return metric at -63.0% versus its period average of -61.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
James Ahlers | Chief Financial Officer | USD 577.28K | 62 | — | — |
Lucinda Warren | Principal Accounting Officer & Chief Business Officer | USD 470.95K | 57 | 250.00K | 9.51% |
Colin G. Sandercock | Senior Vice President of Intellectual Property | USD 449.64K | 69 | — | — |
Shao-Lee Lin | President, CEO & Director | USD 434.2K | 59 | 694.91K | 26.44% |
Rodolfo J. Chaparro | Co-Founder | USD 316.63K | 53 | — | — |
Ronald D. Seidel | Co-Founder | USD 316.63K | 50 | — | — |
Agnes Lee | Chief Officer of Public & Investor Relations | — | — | — | — |
Sumita Ray | Chief Legal & Compliance Officer and Corporate Secretary | — | 52 | 116.70K | 4.44% |
Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board | — | 65 | — | — |
Daniel G. Baker | Interim Chief Development Officer | — | 76 | 100.00K | 3.81% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$599,821.17
Sells
15
$2.43M
Net Transaction Value
−$1.83M
Net selling
Most Active
Lin Shao-Lee
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 12, 26Oct 12, 2026 | Meluzio Michael Vincent Direct | Sell | $32.1K$32,089.20 |
| Oct 12, 26Oct 12, 2026 | Ray Sumita Direct | Sell | $51.7K$51,724.20 |
| Oct 12, 26Oct 12, 2026 | Lin Shao-Lee Direct | Sell | $275K$275,000.00 |
| Oct 12, 26Oct 12, 2026 | Lin Shao-Lee Direct | Sell | $30.5K$30,490.35 |
| Aug 13, 26Aug 13, 2026 | Meluzio Michael Vincent Direct | Sell | $124.6K$124,617.10 |
| Aug 13, 26Aug 13, 2026 | Ray Sumita Direct | Sell | $195.5K$195,514.70 |
| Aug 13, 26Aug 13, 2026 | Ray Sumita Direct | Sell | $124.5$124.52 |
| Aug 13, 26Aug 13, 2026 | Meluzio Michael Vincent Direct | Sell | $44.6K$44,613.03 |
| Aug 13, 26Aug 13, 2026 | Meluzio Michael Vincent Direct | Sell | $93.4$93.39 |
| Aug 13, 26Aug 13, 2026 | Lin Shao-Lee Direct | Sell | $147.5K$147,451.37 |
1–10 of 22
Summary
Insiders reported 7 buys worth $599,821.17 and 15 sells worth $2.43M over the last 12 months. That adds up to net selling of $1.83M. Lin Shao-Lee was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +180.5% | -22.3% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +180.5% over three years. Forward estimates point to Revenue at -22.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Cue Biopharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CUE's management, answered from reported figures.
Who manages CUE?
Cue Biopharma, Inc. (CUE) lists 10 active executives. The top listed executive is Rodolfo J. Chaparro, Co-Founder.
Are CUE insiders buying or selling?
Recent insider activity shows net buying of $43.67M.
Continue the stock analysis
Jump to another research area for this company.